Luminex Corp (LMNX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Luminex Corp (LMNX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8010896
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technologies consist of xMAP technology, xTAG and MultiCode technology. Luminex offers its products to various markets such as clinical diagnostics; pharmaceutical drug discovery; biomedical research including personalized medicine, genomic and proteomic research, biodefense research and food safety. The company sells its products through direct sales channel and strategic distribution partners in North America, Europe and Asia-Pacific. Luminex is headquartered in Texas, the US.

Luminex Corp (LMNX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Luminex Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Luminex Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Luminex Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Luminex Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Luminex Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Luminex Corp, Medical Equipment, Deal Details 12
Partnerships 12
Natural Molecular Testing Enters Into Licensing Agreement With Luminex 12
Merck Enters Into Licensing Agreement With Luminex To Develop Companion Diagnostic Device 13
Genetic Analysis Enters into Agreement with Luminex 14
Luminex Enters into Distribution Agreement with Bio-Techne 15
Affymetrix Enters into Distribution Agreement with Luminex 16
TheraDiag Enters Into Distribution Agreement With Luminex For xTAG RVP And xTAG GPP 17
Luminex Extends Distribution Agreement With EMD Millipore 18
Nanosphere Enters Into Distribution Agreement With Hitachi High-Technologies 19
Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 20
Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 21
Luminex Enters Into Distribution Agreement With Life Technologies 22
Luminex Enters Into An Agreement With Partners HealthCare 23
Equity Offering 24
Nanosphere Raises USD10 Million in Public Offering of Shares 24
Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 26
Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 27
Nanosphere Raises USD20 Million in Public Offering of Shares 28
Nanosphere Completes Public Offering Of Shares For US$30.2 Million 29
Nanosphere Completes Public Offering Of Shares For US$5 Million 31
Nanosphere Completes Public Offering Of Common Stock For US$29 Million 32
Nanosphere Completes Underwritten Public Offering Of US$34.5 Million 33
Asset Transactions 35
Luminex Plans To Sell Newborn Screening Business 35
Acquisition 36
Luminex Acquires Nanosphere in Tender Offer 36
Nanosphere Plans to Sell Itself 38
Luminex Completes Acquisition Of GenturaDx, Molecular Diagnostics Company, For Upto US$60 Million 39
Luminex Completes Acquisition Of EraGen Biosciences 41
Luminex Corp – Key Competitors 42
Luminex Corp – Key Employees 43
Luminex Corp – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Financial Announcements 46
Oct 30, 2017: Luminex Reports Third Quarter 2017 Financial Results 46
Aug 07, 2017: Luminex Reports Second Quarter 2017 Financial Results 47
May 01, 2017: Luminex Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guidance 48
Feb 06, 2017: Luminex Reports Fourth Quarter And Full Year 2016 Results 49
Jan 09, 2017: Luminex Announces Preliminary Revenue for Fourth Quarter 2016 and Issues 2017 Revenue Guidance 50
Oct 31, 2016: Luminex Reports Third Quarter 2016 Results; Raises Full Year Guidance 51
Jul 28, 2016: Luminex Reports Second Quarter 2016 Results 52
May 02, 2016: Luminex Reports First Quarter 2016 Results 53
Feb 01, 2016: Luminex Reports Fourth Quarter And Full Year 2015 Results 54
Product News 55
Oct 26, 2017: Vanderbilt Clinical Labs Choose VERIGENE Blood Culture Tests 55
Apr 07, 2016: Luminex to Showcase CE-IVD Marked ARIES System, Revolutionary Software, and Assays at ECCMID Annual Meeting 56
03/21/2016: Luminex Receives CE-IVD Mark for ARIES HSV 1&2 Assay 57
03/21/2016: Luminex Receives CE-IVD Mark for ARIES System 58
02/22/2016: Luminex Receives Medical Device License for ARIES HSV 1&2 Assay in Canada 59
02/22/2016: Luminex Receives Medical Device License for ARIES System in Canada 60
Product Approvals 61
Mar 21, 2016: Luminex Receives CE-IVD Mark for ARIES System 61
Mar 21, 2016: Luminex Receives CE-IVD Mark for ARIES HSV 1&2 Assay 62
Other Significant Developments 63
Aug 29, 2017: Luminex and Sutter Health Collaborate to Improve Patient Care 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Luminex Corp, Medical Equipment, Key Facts, 2016 2
Luminex Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Luminex Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Luminex Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Luminex Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Luminex Corp, Deals By Market, 2011 to YTD 2017 9
Luminex Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Natural Molecular Testing Enters Into Licensing Agreement With Luminex 12
Merck Enters Into Licensing Agreement With Luminex To Develop Companion Diagnostic Device 13
Genetic Analysis Enters into Agreement with Luminex 14
Luminex Enters into Distribution Agreement with Bio-Techne 15
Affymetrix Enters into Distribution Agreement with Luminex 16
TheraDiag Enters Into Distribution Agreement With Luminex For xTAG RVP And xTAG GPP 17
Luminex Extends Distribution Agreement With EMD Millipore 18
Nanosphere Enters Into Distribution Agreement With Hitachi High-Technologies 19
Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 20
Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 21
Luminex Enters Into Distribution Agreement With Life Technologies 22
Luminex Enters Into An Agreement With Partners HealthCare 23
Nanosphere Raises USD10 Million in Public Offering of Shares 24
Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 26
Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 27
Nanosphere Raises USD20 Million in Public Offering of Shares 28
Nanosphere Completes Public Offering Of Shares For US$30.2 Million 29
Nanosphere Completes Public Offering Of Shares For US$5 Million 31
Nanosphere Completes Public Offering Of Common Stock For US$29 Million 32
Nanosphere Completes Underwritten Public Offering Of US$34.5 Million 33
Luminex Plans To Sell Newborn Screening Business 35
Luminex Acquires Nanosphere in Tender Offer 36
Nanosphere Plans to Sell Itself 38
Luminex Completes Acquisition Of GenturaDx, Molecular Diagnostics Company, For Upto US$60 Million 39
Luminex Completes Acquisition Of EraGen Biosciences 41
Luminex Corp, Key Competitors 42
Luminex Corp, Key Employees 43
Luminex Corp, Other Locations 44
Luminex Corp, Subsidiaries 44

★海外企業調査レポート[Luminex Corp (LMNX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BioTime Inc (BTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • Purplebricks Group plc:企業の戦略・SWOT・財務分析
    Purplebricks Group plc - Strategy, SWOT and Corporate Finance Report Summary Purplebricks Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Croatia Airlines dd:戦略・SWOT・企業財務分析
    Croatia Airlines dd - Strategy, SWOT and Corporate Finance Report Summary Croatia Airlines dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Taiga Biotechnologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary Taiga Biotechnologies Inc (Taiga Biotech) is a biopharmaceutical company that develops protein and cellular therapies. The company develops therapies for diseases including cancers and infectious diseases. Its pipeline products include programs such as stem cell therapy and target specific T …
  • CullenFrost Bankers Inc (CFR):企業の財務・戦略的SWOT分析
    CullenFrost Bankers Inc (CFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Lorain-Medina Rural Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Lorain-Medina Rural Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Erasmus MC-製薬・医療分野:企業M&A・提携分析
    Summary Erasmus MC (Erasmus) is a medical institute that offers patient care, research and educational services. The institute offers graduate and doctoral programs in health sciences, biomedical sciences, molecular medicine and cardiovascular sciences. It conducts research in the areas of biochemis …
  • Atomo Diagnostics Pty Limited:企業の製品パイプライン分析2018
    Summary Atomo Diagnostics Pty Ltd (Atomo Diagnostics) is a medical device company that designs, develops, manufactures, and commercializes in-vitro diagnostic products. The company offers AtomoRapid HIV, a human immunodeficiency virus (HIV) rapid test kit; and AtomoRapid malaria, a kit to test malar …
  • Canadian Tire Corp Ltd (CTC.A):企業の財務・戦略的SWOT分析
    Canadian Tire Corp Ltd (CTC.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ruby Tuesday, Inc.:企業の戦略・SWOT・財務情報
    Ruby Tuesday, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ruby Tuesday, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Andromeda Metals Ltd (ADN):企業の財務・戦略的SWOT分析
    Summary Andromeda Metals Ltd (Andromeda), formerly Adelaide Resources Ltd, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration and development of gold, halloysite-kaolin, lithium, and copper deposits in Australia. Its projects include Moonta …
  • Roka Bioscience Inc:医療機器:M&Aディール及び事業提携情報
    Summary Roka Bioscience Inc (Roka) is a manufacturer and distributor of molecular assays and instruments for food safety industry. The company offers products such as Atlas- automated molecular pathogen detection system, the listeria LSP detection assay, listeria monocytogenes Lmg2 detection assay, …
  • Molnlycke Health Care AB:医療機器:M&Aディール及び事業提携情報
    Summary Molnlycke Health Care AB (Molnlycke), a subsidiary of Investor AB, is a medical device company. The company manufactures and markets single-use surgical and wound care products. It offers a range of surgical and wound care products; infection prevention solutions; prevention and treatment so …
  • Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petro …
  • Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析
    Tasly Pharmaceutical Group Co Ltd (600535) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Canadian Tire Corporation, Limited:戦略・SWOT・企業財務分析
    Canadian Tire Corporation, Limited - Strategy, SWOT and Corporate Finance Report Summary Canadian Tire Corporation, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Nippon Express Co Ltd (9062):企業の財務・戦略的SWOT分析
    Nippon Express Co Ltd (9062) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Entergy Corporation:企業の戦略・SWOT・財務情報
    Entergy Corporation - Strategy, SWOT and Corporate Finance Report Summary Entergy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Specialist Investment Properties PLC:企業の戦略・SWOT・財務分析
    Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report Summary Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆